Definitive Contract 75N93022C00055

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $21,659,151.36 definitive cost-no-fee contract to Duke University to support the "ADVANCED DEVELOPMENT OF A NEUTRALIZING ANTIBODY VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES." This contract, which does not have a set-aside designation, will run through September 18, 2026. Duke University's Office of Research Administration Division will serve as the prime contractor on this project, which is aligned with NIAID's mission to conduct and support research to understand, treat, and prevent infectious diseases. The contract stems from a pre-solicitation notice posted under the Small Business Innovation Research (SBIR) program, which sought proposals from small businesses for biomedical and public health research topics. However, the actual award was made directly to Duke University, a leading research institution, rather than a small business.